Samrat Pharmachem [SAMRATPH] vs Styrenix Performance [STYRENIX] Detailed Stock Comparison
Samrat Pharmachem
BSE
Loading...
Styrenix Performance
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Samrat Pharmachem wins in 8 metrics, Styrenix Performance wins in 10 metrics, with 0 ties. Styrenix Performance appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Samrat Pharmachem | Styrenix Performance | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 13.81 | 20.53 | Samrat Pharmachem |
| Price-to-Book Ratio | 1.37 | 3.97 | Samrat Pharmachem |
| Debt-to-Equity Ratio | 13.81 | 34.02 | Samrat Pharmachem |
| PEG Ratio | N/A | -1.35 | N/A |
| EV/EBITDA | 13.86 | 14.82 | Samrat Pharmachem |
| Profit Margin (TTM) | 1.72% | 7.00% | Styrenix Performance |
| Operating Margin (TTM) | -0.06% | 7.61% | Styrenix Performance |
| EBITDA Margin (TTM) | N/A | 7.61% | N/A |
| Return on Equity | 9.91% | 20.14% | Styrenix Performance |
| Return on Assets (TTM) | 5.85% | 10.26% | Styrenix Performance |
| Free Cash Flow (TTM) | $-105.99M | $-3.82B | Samrat Pharmachem |
| Dividend Yield | 0.29% | 1.78% | Styrenix Performance |
| 1-Year Return | -30.15% | -3.65% | Styrenix Performance |
| Price-to-Sales Ratio (TTM) | 0.35 | 1.44 | Samrat Pharmachem |
| Enterprise Value | $1.08B | $49.27B | Styrenix Performance |
| EV/Revenue Ratio | 0.38 | 1.53 | Samrat Pharmachem |
| Gross Profit Margin (TTM) | 3.39% | 27.12% | Styrenix Performance |
| Revenue per Share (TTM) | $908 | $1,860 | Styrenix Performance |
| Earnings per Share (Diluted) | $23.02 | $128.45 | Styrenix Performance |
| Beta (Stock Volatility) | -0.32 | 0.77 | Samrat Pharmachem |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Samrat Pharmachem vs Styrenix Performance Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Samrat Pharmachem | -0.91% | -6.16% | -12.87% | -14.81% | -11.45% | -17.63% |
| Styrenix Performance | -0.67% | -2.72% | -15.60% | -9.75% | 7.41% | -12.44% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Samrat Pharmachem | -30.15% | -57.38% | 181.12% | 931.84% | 1,575.06% | 1,070.42% |
| Styrenix Performance | -3.65% | 188.91% | 407.99% | 249.98% | 653.99% | 2,107.11% |
Performance & Financial Health Analysis: Samrat Pharmachem vs Styrenix Performance
| Metric | SAMRATPH | STYRENIX |
|---|---|---|
| Market Information | ||
| Market Cap | ₹982.37M | ₹46.38B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 2,495 | 20,845 |
| 90 Day Avg. Volume | 2,791 | 23,307 |
| Last Close | ₹319.50 | ₹2,652.00 |
| 52 Week Range | ₹302.05 - ₹646.00 | ₹2,220.50 - ₹3,498.00 |
| % from 52W High | -50.54% | -24.19% |
| All-Time High | ₹1,250.00 (Sep 19, 2022) | ₹3,498.00 (Jun 09, 2025) |
| % from All-Time High | -74.44% | -24.19% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.06% | 0.35% |
| Quarterly Earnings Growth | -0.14% | -0.15% |
| Financial Health | ||
| Profit Margin (TTM) | 0.02% | 0.07% |
| Operating Margin (TTM) | 0.00% | 0.08% |
| Return on Equity (TTM) | 0.10% | 0.20% |
| Debt to Equity (MRQ) | 13.81 | 34.02 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹232.02 | ₹663.93 |
| Cash per Share (MRQ) | ₹1.70 | ₹61.62 |
| Operating Cash Flow (TTM) | ₹1.26M | ₹-3,519,400,000 |
| Levered Free Cash Flow (TTM) | ₹71.12M | ₹2.35B |
| Dividends | ||
| Last 12-Month Dividend Yield | 0.29% | 1.78% |
| Last 12-Month Dividend | ₹1.00 | ₹59.00 |
Valuation & Enterprise Metrics Analysis: Samrat Pharmachem vs Styrenix Performance
| Metric | SAMRATPH | STYRENIX |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 13.81 | 20.53 |
| Forward P/E | N/A | N/A |
| PEG Ratio | N/A | -1.35 |
| Price to Sales (TTM) | 0.35 | 1.44 |
| Price to Book (MRQ) | 1.37 | 3.97 |
| Market Capitalization | ||
| Market Capitalization | ₹982.37M | ₹46.38B |
| Enterprise Value | ₹1.08B | ₹49.27B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 0.38 | 1.53 |
| Enterprise to EBITDA | 13.86 | 14.82 |
| Risk & Other Metrics | ||
| Beta | -0.32 | 0.77 |
| Book Value per Share (MRQ) | ₹232.02 | ₹663.93 |
Financial Statements Comparison: Samrat Pharmachem vs Styrenix Performance
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | SAMRATPH | STYRENIX |
|---|---|---|
| Revenue/Sales | ₹712.03M | ₹9.44B |
| Cost of Goods Sold | ₹687.86M | ₹6.88B |
| Gross Profit | ₹24.17M | ₹2.56B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹-346,000 | ₹717.50M |
| EBITDA | ₹185,000 | ₹998.40M |
| Pre-Tax Income | ₹-3.64M | ₹705.40M |
| Income Tax | ₹357,000 | ₹186.20M |
| Net Income (Profit) | ₹-3.99M | ₹519.20M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | SAMRATPH | STYRENIX |
|---|---|---|
| Cash & Equivalents | ₹483,000 | ₹976.50M |
| Total Current Assets | ₹1.03B | ₹13.61B |
| Total Current Liabilities | ₹495.83M | ₹6.61B |
| Long-Term Debt | ₹0 | ₹3.77B |
| Total Shareholders Equity | ₹718.00M | ₹11.68B |
| Retained Earnings | N/A | ₹7.40B |
| Property, Plant & Equipment | N/A | ₹8.53B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | SAMRATPH | STYRENIX |
|---|---|---|
| Operating Cash Flow | N/A | ₹251.00M |
| Capital Expenditures | N/A | ₹-380.00M |
| Free Cash Flow | N/A | ₹870.00M |
| Debt Repayment | N/A | ₹-1.15B |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | SAMRATPH | STYRENIX |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 2,495 | 20,845 |
| Average Daily Volume (90 Day) | 2,791 | 23,307 |
| Shares Outstanding | 3.09M | 17.59M |
| Float Shares | 1.26M | 8.96M |
| % Held by Insiders | 0.59% | 0.49% |
| % Held by Institutions | 0.00% | 0.13% |
Dividend Analysis & Yield Comparison: Samrat Pharmachem vs Styrenix Performance
| Metric | SAMRATPH | STYRENIX |
|---|---|---|
| Last 12-Month Dividend | ₹1.00 | ₹59.00 |
| Last 12-Month Dividend Yield | 0.29% | 1.78% |
| 3-Year Avg Annual Dividend | ₹1.67 | ₹77.67 |
| 3-Year Avg Dividend Yield | 0.17% | 3.38% |
| 3-Year Total Dividends | ₹5.00 | ₹233.00 |
| Ex-Dividend Date | Sep 19, 2024 | Dec 17, 2024 |